Segmentation by type classifies Dental Regenerative Products into five distinct technology families. Growth‑factor formulations—recombinant proteins such as BMP‑2, PDGF, and FGF—are the most mature category, generating roughly 30 % of market value due to established regulatory pathways and broad clinical acceptance. Stem‑cell therapies, encompassing autologous dental pulp stem cells and allogeneic mesenchymal stem cells, contribute about 25 % and are gaining traction as procurement and cryopreservation processes become cost‑effective. Scaffold materials—including collagen, hyaluronic acid, and synthetic polymers—represent 20 % of sales, reflecting their role as delivery matrices that enable spatial control of cell and factor placement. Gene‑therapy approaches remain exploratory but command an estimated 5 % of the market, primarily within clinical trials targeting localized expression of regenerative cues. The remaining 20 % consists of combination products that integrate two or more of the above technologies, offering synergistic outcomes and commanding premium pricing. Together, these types shape the overall market size by diversifying revenue streams and supporting incremental innovation.
